Gene
IDH2
IDH2 is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (2), Assay-provider ledger (28), Actionable biomarkers (4), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention IDH2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start and 1 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 15 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 16 of 8,738 | 0.18% | not measured | |
| 2025 | 18 of 8,875 | 0.20% | not measured | |
| 2024 | 11 of 8,597 | 0.13% | not measured | |
| 2023 | 15 of 8,275 | 0.18% | 38 of 11,460 | 0.33% |
| 2022 | 5 of 8,285 | 0.06% | 40 of 13,598 | 0.29% |
| 2021 | 18 of 8,692 | 0.21% | 51 of 15,045 | 0.34% |
| 2020 | 16 of 7,640 | 0.21% | 41 of 14,459 | 0.28% |
| 2019 | 18 of 7,300 | 0.25% | 42 of 12,159 | 0.35% |
| 2018 | 12 of 6,927 | 0.17% | 35 of 11,854 | 0.30% |
| 2017 | 7 of 6,558 | 0.11% | 30 of 11,595 | 0.26% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (2)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| Oncomine Dx Target Test | IDH2 | Life Technologies Corporation | Astrocytoma and Oligodendroglioma | 2024-09-18 |
| Abbott RealTime IDH2 | IDH2 | Abbott Molecular, Inc. | Acute Myeloid Leukemia | 2017-08-01 |
Assay-provider ledger (28)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validation | 1 | June 01, 2026 |
| Biocartis | Diagnostic provider | Clinical validationAnalytical validation | 1 | May 25, 2024 |
| Promega | Reagent supplier | Analytical validation | 1 | November 08, 2021 |
| Thermo Fisher | Reagent supplier | Analytical validation | 1 | November 08, 2021 |
| Clinical Cancer Genomics Laboratory, University of California, San Francisco | Not a company | Analytical validation | 1 | August 01, 2021 |
Showing 5 of 28 assay-provider companies.
Actionable biomarkers (4)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| IDH2 oncogenic mutation | Venetoclax | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
| IDH2 (R172) | Dasatinib | response-associated | biliary tract neoplasm | Cancer Genome Interpreter |
| IDH2 oncogenic mutation | Dasatinib | response-associated | cholangiocarcinoma | Cancer Genome Interpreter |
| IDH2 (R140K,R172K) | Ag-221 | response-associated | hematologic disease | Cancer Genome Interpreter |
Trial mentions (158)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01089244 | Trial biospecimen (AACT) |
| NCT06780930 | Trial eligibility (AACT) |
| NCT06672146 | Trial eligibility (AACT) |
| NCT04968366 | Trial eligibility (AACT) |
| NCT04015700 | Trial eligibility (AACT) |
Showing 5 of 158 trial mentions.
Target-disease associations (510)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 2-hydroxyglutaric aciduria | genetic, familial or congenital disease | genomics england |
| Absence of circulating granulocytes | phenotype | GWAS credible sets |
| Alpha-thalassemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alpha-thalassemia - intellectual disability syndrome linked to chromosome 16 | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alpha-thalassemia - myelodysplastic syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 510 associations.
Vendor sourcing (575)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic (ClinVar ID: VCV000014716.9, PMID:20847235, PS1). It is... | View ClinVar record SCV002012059.1 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance score of ≤2 * IDH2 (R140 or IDH R172) mutated AML disease status as determined by... | View trial NCT04092179 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | IDH2 | View trial NCT04092179 |
| Abramson Cancer Center | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Prior histopathologically proven diagnosis of astrocytoma (grade 2-4) or oligodendroglioma (grade 2-3) according to the World Health Organization (WHO)... | View trial NCT05345002 |
| Abramson Cancer Center | Trial collaborator | Mentioned in trial textTrial free-text mention | IDH2 | View trial NCT05345002 |
Showing 5 of 575 sourcing records.
Trial-cited literature (408)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial. | Blood neoplasia | 2026 | 2 |
| Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study. | American journal of hematology | 2026 | 0 |
| Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | 27 |
| Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial. | The Lancet. Oncology | 2025 | 21 |
| HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study. | Med (New York, N.Y.) | 2025 | 9 |
Showing 5 of 408 papers.
Protein variant mentions (18)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A232V | 1 | 2015 | PMID 25741868 |
| p.D225N | 1 | 2015 | PMID 25741868 |
| p.F196L | 1 | 2015 | PMID 25741868 |
| p.G302A | 1 | 2022 | PMID 35888045 |
| p.K120M | 1 | 2019 | PMID 31817761 |
Showing 5 of 18 variants.
Literature-extracted relations (160)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| NIVOLUMAB | Chemical | negative_correlate |
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas. | 2024 |
| AZACITIDINE (VIDAZA) | Chemical | negative_correlate |
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. | 2021 |
| Chloroquine | Chemical | associate |
Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with <i>IDH1</i>-mutated or <i>IDH2</i>-mutated solid tumours. | 2017 |
| METFORMIN | Chemical | associate |
Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with <i>IDH1</i>-mutated or <i>IDH2</i>-mutated solid tumours. | 2017 |
| AZACITIDINE (VIDAZA) | Chemical | negative_correlate |
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in <i>IDH2</i>- and <i>TET2</i>-Mutant Acute Myeloid Leukemia. | 2017 |
Showing 5 of 160 relation assertions.
Organizations publishing (449)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 48 | 2012 to 2025 |
| The University of Texas System | Academic | 47 | 2013 to 2026 |
| Dana-Farber Cancer Institute | Other | 37 | 2009 to 2025 |
| Harvard Medical School | Academic | 23 | 2012 to 2024 |
| Mass General Brigham | Hospital | 22 | 2012 to 2024 |
Showing 5 of 449 organizations.
Where IDH2 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- psychiatric disorder
- respiratory or thoracic disease
- urinary system disease
436 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects and human sample screening reference.